Cancer antiangiogenic therapy

Identification of the active component of Neovastat may elucidate its specific mode of acfion and potentially limit the side effects identified at the present time. This is particularly pertinent if, as expected, life-long administration is required, because the effects of chronic exposure and interactions between Neovastat and other therapies are not yet known. The positive safety profile and fhe oral administration route of Neovastat, however, are advantages in comparison with current therapies and some angiogenesis inhibitors. Thus, should antiangiogenic therapy become a mainstream therapy, Neovastat could play a substantial role in the treatment of cancer. 

Boehm T, Folkman J, Browder T, et al. Antiangiogenic therapy of experimental cancer does not induce acquired resistance. Nature 1997 390 404-407. 

Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999 59(21) 5412-5416. 

Herbst RS, Takeuchi H, Teicher BA. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models. Cancer Chem Pharm 1998,41 497-504. 

Rajkumar SV, Witzig TE. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 2000 26(5) 351-62. 

Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on inerstitial hypertension, peritumor edema, and lymphaticmetastasis insights from a mathematical model. Cancer Res 2007 67 2729-2735. 

Id. Folkman J. Antiangiogenic therapy experimental and clinical studies. 42nd Annual Clinical Conference 52nd Annual Symposium on Fundamental Cancer Research. The University of Texas MD Anderson Comprehensive Cancta Center Cancta Research at the Millenium. Houston TX Jan 9-12, 2000 pp 56—57. 

Li M et al (2002a) Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 8 3570-3578... 

Jain RK (2005) Normalization of tumor vasculature An emerging concept in antiangiogenic therapy. Science 307 58-62 Kim CY, Tsai MH, Osmanian C, Graeber TG, Lee JE, Giffard RG, DiPaolo JA, Peehl DM, Giaccia AJ (1997) Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions. Cancer Res 57 4200-4204... 

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23 8136-8139... 

Ledzewicz, U., and H. Schattler, Antiangiogenic Therapy in Cancer Treatment as an Optimal Control Problem, SIAM J. Control Optim.,46,1052(2007). 

Kerbel, R.S. (2006). Antiangiogenic therapy a universal chemosensitization strategy for cancer Science 572, 1171-1175. 

FiggWD, Pluda JM, Sartor O (1999) In Teicher BA (ed), Antiangiogenic Agents in Cancer Therapy. Humana, Totowa, NJ, p. 371... 

Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992 52 6702-6704. 

---